Search research articles
Contact Us
Filters
Showing results (211-220 of 234) with videos related to
Page
of 24
Sort By:
ESMO Real World Data and Digital Oncology
|
April 3, 2026
Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine care
L Sellmann, D Marschner, U M Martens, et al.
British Journal of Cancer
|
July 14, 2011
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial
S Stintzing, L Fischer von Weikersthal, U Vehling-Kaiser, et al.
ESMO Open
|
April 19, 2023
Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry
K Riecke, V Müller, T Neunhöffer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 30, 2018
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
J W Holch, I Ricard, S Stintzing, et al.
ESMO Open
|
May 17, 2025
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study
T Decker, C Brucker, A Engel, et al.
Applied and Environmental Microbiology
|
September 15, 2021
Genomes of Novel <i>Myxococcota</i> Reveal Severely Curtailed Machineries for Predation and Cellular Differentiation
Chelsea L Murphy, R Yang, T Decker, et al.
Journal of Cancer Research and Clinical Oncology
|
May 13, 2014
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
J C von Einem, V Heinemann, L Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 3, 2017
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
S Stintzing, L Miller-Phillips, D P Modest, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2025
Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO
M M Germani, V Heinemann, D Rossini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2017
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)
D P Modest, I Ricard, S Stintzing, et al.
Page
of 24
Search research articles
Search
Showing results (211-220 of 234) with videos related to
Sort By:
Page
of 24
ESMO Real World Data and Digital Oncology
|
April 3, 2026
Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine care
L Sellmann, D Marschner, U M Martens, et al.
British Journal of Cancer
|
July 14, 2011
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial
S Stintzing, L Fischer von Weikersthal, U Vehling-Kaiser, et al.
ESMO Open
|
April 19, 2023
Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry
K Riecke, V Müller, T Neunhöffer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 30, 2018
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
J W Holch, I Ricard, S Stintzing, et al.
ESMO Open
|
May 17, 2025
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study
T Decker, C Brucker, A Engel, et al.
Applied and Environmental Microbiology
|
September 15, 2021
Genomes of Novel <i>Myxococcota</i> Reveal Severely Curtailed Machineries for Predation and Cellular Differentiation
Chelsea L Murphy, R Yang, T Decker, et al.
Journal of Cancer Research and Clinical Oncology
|
May 13, 2014
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
J C von Einem, V Heinemann, L Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 3, 2017
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
S Stintzing, L Miller-Phillips, D P Modest, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2025
Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO
M M Germani, V Heinemann, D Rossini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2017
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)
D P Modest, I Ricard, S Stintzing, et al.
Page
of 24